---
title: "Medicare Surge Meets Patent Clash: Health Tech Trio's Quiet Moves"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301817940.md"
description: "Tonix expands Medicare coverage to 32M while fending off generic challenges; Ribbon extends merger deadline to 2027 after shareholder vote; TSS scales data centers for healthcare AI infrastructure despite revenue volatility."
datetime: "2026-10-14T09:20:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301817940.md)
  - [en](https://longbridge.com/en/news/301817940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301817940.md)
generator: "portal-rs"
---

# Medicare Surge Meets Patent Clash: Health Tech Trio's Quiet Moves

As health tech navigates Medicare expansion and patent battles, three companies are carving distinct paths. Tonix Pharmaceuticals (TNXP.US) boosted TONMYA's Medicare coverage to 32 million Americans—58% of the U.S. market—but faces Dr. Reddy's Paragraph IV challenge to its patents after Q2 revenue surged 197% year-on-year. Ribbon Acquisition Corp (RIBB.US) extended its DRC Medicine merger deadline to January 2027 following shareholder approval to eliminate redemption thresholds, while securing a $4.1 million equity line to address liquidity gaps. Meanwhile, TSS, Inc. (TSSI.US) leased 380,000 square feet of data center space in Georgetown to support AI-driven healthcare analytics, maintaining EBITDA growth despite quarterly revenue fluctuations.

### Related Stocks

- [RIBB.US](https://longbridge.com/en/quote/RIBB.US.md)
- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)
- [TSSI.US](https://longbridge.com/en/quote/TSSI.US.md)

## Related News & Research

- [Tonix Pharmaceuticals to Present TONMYA Phase 3 Analysis at IASP Pain Congress](https://longbridge.com/en/news/302279890.md)
- [Tonix Pharma Faces Generic TONMYA Patent Challenge](https://longbridge.com/en/news/300830948.md)
- [Tonix signs second managed Medicare agreement for TONMYA, adding 21 million covered lives](https://longbridge.com/en/news/299753832.md)
- [Ribbon Acquisition holds extraordinary shareholder meeting with 63.71% quorum present](https://longbridge.com/en/news/298764629.md)
- [Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears](https://longbridge.com/en/news/298780449.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**